UCB Biopharma SRL

Quick facts

Marketed products

• Brivaracetam oral solution

Phase 3 pipeline

• brivaracetam (BRV) tablet · Neurology
  Brivaracetam is a selective, high-affinity SV2A receptor agonist.
• Brivaracetam Film-coated tablet · Neurology
  Brivaracetam binds to synaptic vesicle protein 2A (SV2A) in the brain to reduce neuronal excitability and prevent seizures.
• DZP · Neurology, Psychiatry
  DZP is a benzodiazepine that enhances GABAergic neurotransmission by potentiating the effect of GABA at GABA-A receptors in the central nervous system.
• Staccato alprazolam · Psychiatry / Neurology
  Staccato alprazolam is a rapidly-absorbed inhaled formulation of alprazolam that binds to GABA-A receptors in the central nervous system to enhance inhibitory neurotransmission.
• zilucoplan (RA101495) · Immunology
  Zilucoplan is a sphingosine 1-phosphate receptor modulator.

Phase 2 pipeline

• UCB0022

Phase 1 pipeline

• Bimekizumab regimen 1 iv
• Bimekizumab regimen 2 iv
• Bimekizumab regimen 3 sc
• ginisortamab · Other
• Minzasolmin tablet formulation under fasting condition
• Pharmacokinetics of certolizumab pegol
• UCB1381
• UCB5285
• UCB7853
• UCB9741

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• UCB Biopharma SRL portfolio CI brief
• UCB Biopharma SRL pipeline updates RSS